GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine–induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, GLP-1RAs have demonstrated considerable therapeutic promise in animal models of both PD and AD.427–429”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to its effects on metabolic regulation, GLP-1, when synthesized within the brain, exhibits neuroprotective properties.397,427,431”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 10×
“These and other actions are mediated through the G protein-coupled GLP-1R, and Ex-4 has demonstrated therapeutic value in T2DM (7).”
BackgroundMethodInfluentialDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“GLP-1R mRNA occurs widely throughout the brains of rodents (9) and humans (6,7,10), and both GLP-1 and Ex-4 can readily enter the brain (11) to modify feeding and satiety (12).”
BackgroundJavitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263 · cited 2×
“Administration of MPTP in mice induces a consistent dopaminergic cell loss that parallels many aspects of PD (16,20).”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 3×
“Although T2DM now occurs more often in the young, the incidence rises dramatically with age, along with that of many of other conditions, including acute and chronic neurologic disorders, exemplified by stroke (2), Parkinson’s disease (PD) and Alzheimer’s disease (AD) (3,4), which, like T2DM, were once considered rela…”
BackgroundD'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“These neurotrophic/protective actions are in accordance with previous findings establishing that GLP-1R stimulation protects hippocampal neurons from amyloid- peptide–, Fe2 -, and glutamate-induced toxicity (15,32,33).”
BackgroundResultInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
BackgroundSelf-citationCell death in the nervous system
Bredesen, D. E., Rao, R. V., & Mehlen, P. (2006) · Nature · doi:10.1038/nature05293 · Cited by 636 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
Background
Research works printed but not linked: 2
- R Sicree, J Shaw, P Zimmet Diabetes Atlas, ed D Gan (International Diabetes Federation, 3rd Ed, Brussels), pp. 15–103 (2006).
- 10.1210/endo.140.3.6550 · doi:10.1210/endo.140.3.6550 · Paper page
Cited by
Items 401–500 of 629
Hajare, S., & Kulkarni, Y. A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149975 · Cited by 19
Irin, A. K., Kodamullil, A. T., Gündel, M., & Hofmann‐Apitius, M. (2015) · Journal of Immunology Research · doi:10.1155/2015/737168 · Cited by 19
“GLP1R is also known to play a role in dopamine secretion and inhibiting dopaminergic degeneration [56].”
BackgroundChan, S.-Y., Ou, S., Chen, Y., & Shih, C.-J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.05.062 · Cited by 19
Victorino, D. B., Nejm, M. B., Guimarães‐Marques, M., Scorza, F. A., & Scorza, C. A. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00374-5 · Cited by 19
Homolak, J., Perhoč, A. B., Knezović, A., Barilar, J. O., & Šalković‐Petrišić, M. (2021) · Antioxidants · doi:10.3390/antiox10071118 · Cited by 19
“[45] Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al.”
BackgroundBakıner, O., Bozkırlı, E., Gıray, S., Arlıer, Z., Kozanoğlu, İ., Sezgin, N., Sarıtürk, Ç., & Ertörer, M. E. (2013) · Critical Care · doi:10.1186/cc12795 · Cited by 19
“Recently demonstrated neuroprotective properties of GLP-1 via GLP-1 receptors on neurons was the other reason [20-24].”
BackgroundYang, M., Jia, M., Cai, M., Feng, X., Huang, L., & Yang, J. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06840-9 · Cited by 18
“…neuronal death induced by 6-hydroxydopamine, and administration of GLP-1 via the lateral ventricle protects mice from MPTP-induced neuronal loss (Li et al. 2009). induce morphological alterations in astrocytes, which play an important role in the pathophysiology of neuropsychiatric disorders.”
Wyse, R. K. H., Isaacs, T., Barker, R. A., Cookson, M., Dawson, T. M., Devos, D., Dexter, D. T., Duffen, J., Federoff, H. J., Fiske, B. K., et al. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230363 · Cited by 18
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Ribarič, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084358 · Cited by 18
Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease
Verma, A., & Goyal, A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176936 · Cited by 18
Xiao, F., Zha, Q., Zhang, Q., Wu, Q., Chen, Z., Yang, Y., Yang, K., & Liu, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.709741 · Cited by 18
Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes
Caputo, V., Termine, A., Strafella, C., Giardina, E., & Cascella, R. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i5.155 · Cited by 18
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 17
“Hypoxia and formation of 6-hydroxydopamine cause cell death, and GLP-1 and exendin-4 protected hypoxia-induced cell death, and this effect disappeared in the cells from GLP-1R knockout (−/−) mice [156].”
Huang, Y., Wang, X., Li, W., Yue, F., Wang, M., & Zhou, F. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479670 · Cited by 17
“24 25–28 In this study, we delicately designed and synthesized an Exendin-4 peptide-conjugated DFO-loaded nanoparticle system (Ex-4@DFO NPs) to target brain effectively for PD treatment.”
MethodIschemic Stroke and Sleep: The Linking Genetic Factors
Коростовцева, Л. С. (2021) · Cardiology and Therapy · doi:10.1007/s40119-021-00231-9 · Cited by 17
Genetic Variation in the GCG and in the GLP1R Genes and Antipsychotic-Induced Weight Gain
Brandl, E. J., Tiwari, A. K., Chowdhury, N. I., Zai, C. C. H., Lieberman, J. A., Meltzer, H. Y., Kennedy, J. L., & Müller, D. J. (2014) · Pharmacogenomics · doi:10.2217/pgs.13.247 · Cited by 17
Neuroprotective Effects of rhGLP‐1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury
Jiang, D., Wang, Y., Zang, Y., Liu, X., Zhao, L., Wang, Q., Liu, C., Feng, W., Yin, X., & Fang, Y. (2016) · Drug Development Research · doi:10.1002/ddr.21297 · Cited by 17
“GLP-1 receptor stimulation improves functional deficits in in vivo and in vitro models of Parkinson’s disease and ischemic stroke [Li et al., 2009, 2010].”
BackgroundSelf-citationAnimal venoms: therapeutic tools for tackling Parkinson’s disease
Amaral, H. D. O., Monge‐Fuentes, V., Mayer, A. B., Campos, G. A. A., Lopes, K. S., Camargo, L. C., Schwartz, M. F., Galante, P., & Mortari, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.004 · Cited by 17
Shang, P., Baker, M. R., Banks, S. A., Hong, S., & Choi, D. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21035 · Cited by 17
Majumdar, M., & Badwaik, H. R. (2024) · Current Drug Targets · doi:10.2174/0113894501312703240826070530 · Cited by 16
Fiory, F., Mirra, P., Nigro, C., Pignalosa, F. C., Zatterale, F., Ulianich, L., Prevete, N., Formisano, P., Bèguinot, F., & Miele, C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27898 · Cited by 16
“Evidence in literature shows that insulin‐resistant states, such as obesity and T2D, are characterized by a decreased TH expression and, consequently, an altered dopaminergic function (Glanville & Anderson, 1986; Li et al., 2009b; Morris et al., 2011; Nascimento et al., 2011).”
BackgroundNovel approaches to counter protein aggregation pathology in Parkinson's disease
Stott, S., Wyse, R. K. H., & Brundin, P. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.007 · Cited by 16
Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R
Zhang, H., Liu, Y., Cheng, L., Ma, X., & Luo, X. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.11.008 · Cited by 16
Zhu, C., Tao, H., Rong, S., Xiao, L., Li, X., Jiang, S., Guo, B., Wang, L., Ding, J., Gao, C., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.694476 · Cited by 16
El‐Shorbagi, A., Chaudhary, S., Alshemali Khadeja, A., Alabdulrazzaq Razan, F., & Alqahtani Fatma, Y. (2020) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2020.1010015 · Cited by 16
“Calcium Ca2+ Calcium plays an important role in protecting neuron cells; reports have suggested that an increase in brain Ca2+ levels promotes the aggregation of α-synuclein (Athauda et al., 2017; Bertilsson et al., 2008; Hunot et al., 1997; Li et al., 2009; Nath et al., 2011).”
BackgroundLiu, C., Liu, W.-H., Yang, W., Chen, L., Xue, Y., & Chen, X. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109946 · Cited by 15
“Previous studies revealed that GLP-1 exerts antiparkinsonian effects in both 6-OHDA and MPTP parkinsonian animal models (Li et al., 2009, 2010).”
Obesity and Depression: Common Link and Possible Targets
Jitte, S., Keluth, S., Bisht, P., Wal, P., Singh, S., Murti, K., & Kumar, N. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273291985240430074053 · Cited by 15
Turcano, P., Savica, R., & Benarroch, E. E. (2024) · Neurology · doi:10.1212/wnl.0000000000209781 · Cited by 15
Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases
Hölscher, C. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.01.007 · Cited by 15
Use of Glucagon-Like Peptide-1 Agonists to Improve Islet Graft Performance
Wang, Y., Qi, M., McGarrigle, J. J., Rady, B., Davis, M., Vaca, P., & Oberholzer, J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0402-z · Cited by 15
Self-citationNeuroprotective role of (Val 8 ) GLP-1-Glu-PAL in an in vitro model of Parkinson′s disease
Liu, Y., Li, L., Liu, K., Zhao, J., Hölscher, C., & Li, G. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.177742 · Cited by 15
“, 2014) and in animal models of Parkinson’s (Bertilsson et al., 2008; Li et al., 2009) and Alzheimer’s diseases (McClean et al.”
Recent Advances in Drug Repurposing for Parkinson’s Disease
Chen, X., Gumina, G., & Virga, K. G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180719144850 · Cited by 15
Khalilnezhad, A., & Taşkıran, D. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1543671 · Cited by 15
“amine-induced cell death through its anti-apoptotic effects [43].”
BackgroundChen, S., Tang, Q., Wang, Y., Zheng, X., Chen, S., Sun, Y., Yao, W., & Gao, X. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.012 · Cited by 16
Self-citationProtective Effects of Incretin Against Age-Related Diseases
Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15
Status and future directions of clinical trials in Parkinson's disease
Söderbom, G. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.02.009 · Cited by 15
Darsalia, V., Larsson, M., Klein, T., & Patrone, C. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0674-3 · Cited by 15
“showed that the activation of GLP-1R by exendin-4 could also reduce brain damage in a mouse stroke model [2].”
BackgroundLi, Y., Vaughan, K. L., Wang, Y., Yu, S., Bae, E.-K., Tamargo, I. A., Kopp, K. O., Tweedie, D., Chiang, C., Schmidt, K. T., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01120-4 · Cited by 14
“Cellular studies in immortal and primary neuron cultures Protective action of gliptins + incretins in human SH‑SY5Y cell culture Previous studies have demonstrated that human SH-SY5Y neuronal cells possess functional receptors for GLP-1 and GIP [23, 24, 57, 58].”
BackgroundMethodSelf-citationLu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Hammad, B. F., Zafar, N., Ullah, M., Faisal, S. J., Iftikhar, F., Waheed, H., Muzaffar, M. W., Ahmed, K., Ashraf, F., Zahid, K., et al. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1590530 · Cited by 14
Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
Ahn, C. H., & Lim, S. K. (2019) · Journal of Stroke · doi:10.5853/jos.2019.00038 · Cited by 14
Bagaméry, F., Varga, K., Kecsmár, K., Vincze, I., Szökő, É., & Tábi, T. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03269-2 · Cited by 14
“In in vitro studies on neural cell cultures its protective effects against various damaging conditions like oxidative stress [16, 17], hypoxia [18] or Aβ insult [16, 19] among others was revealed.”
BackgroundEffect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model
Lamontagne‐Proulx, J., Coulombe, K., Dahhani, F., Côté, M., Guyaz, C., Tremblay, C., Marzo, V. D., Flamand, N., Calon, F., & Soulet, D. (2021) · Nutrients · doi:10.3390/nu13124218 · Cited by 14
“A reduction in TH+ neurons and a decrease of brain dopamine content induced by MPTP were fully prevented by treatment with a GLP-1R agonist [89].”
BackgroundPradeloux, S., Coulombe, K., Ouamba, A. J. K., Isenbrandt, A., Calon, F., Roy, D., & Soulet, D. (2024) · Nutrients · doi:10.3390/nu16193309 · Cited by 15
Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy
Zhou, Y., Li, Z., Cao, X., Ma, H., White, P. F., Xu, X., Jiang, Y., Sun, X.-J., & Cui, Y. (2018) · Brain Research · doi:10.1016/j.brainres.2018.11.007 · Cited by 14
Harkavyi, A., Rampersaud, N., & Whitton, P. S. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/407152 · Cited by 14
“Neuroprotective effects have been shown in vitro to be GLP-1R dependent by the use of the GLP-1R selective antagonist EX-(9-39) and alsomore recently inGLP1R knockout mice [5].”
BackgroundMcGrath, R. T., HOCKING, S. L., Priglinger, M. L., Day, S., Herkes, G., Krause, M., & Fulcher, G. R. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008203 · Cited by 14
Rowlands, J., Cruzat, V. F., Carlessi, R., & Newsholme, P. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.015 · Cited by 14
Avilés-Olmos, I., Espinoza‐Vinces, C., Portugal, L. R., & Luquin, M. R. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01606-1 · Cited by 13
“…in addressing the underlying mechanism and symptoms associated with PD. GLP-1 is a peptide hormone that easily crosses the blood-brain barrier, making GLP-1RAs good candidates for treating several neu - rodegenerative diseases like PD and Alzheimer’s disease, brain injury, and stroke [ 40 ].”
Exendin-4 Improves Cognitive Function of Diabetic Mice via Increasing Brain Insulin Synthesis
Peng, X., Shi, X., Huang, J., Zhang, S., Yan, Y., Ma, D., Xu, W., Xu, W., Dong, K., Tao, J., et al. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210929150004 · Cited by 13
Chen, Y., Shen, J., Qi, G.-X., Zha, Q., Zhang, C., Yao, W., Gao, X., & Chen, S. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108335 · Cited by 13
Khan, M. A., Haider, N., Singh, T., Bandopadhyay, R., Ghoneim, M. M., Alshehri, S., Taha, M., Ahmad, J., & Mishra, A. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01180-z · Cited by 13
Gao, C., & Shen, J. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.02.007 · Cited by 13
Fang, Y., Liu, X., Zhao, L., Wei, Z., Jiang, D., Shao, H., Zang, Y., Xu, J., Wang, Q., Liu, Y., et al. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2017.21.5.475 · Cited by 13
“It has been reported recently that GLP-1 receptor agonists (Exendin-4 / liraglutide) have neuroprotective effect on cerebral ischemia models [17-20], they could reduce tissue stress injury and reduce brain infarction volume, possibly through anti-oxidative effects and anti-apoptotic effects; as such, they may have a f…”
BackgroundTherapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats
Шекунова, Е. В., Кашкин, В. А., Muzhikyan, A., Макарова, М. Н., Balabanyan, V. Y., & Makarov, V. G. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172835 · Cited by 13
A Review of the Recent Advances in the Pharmacological Management of Parkinson’s Disease
Li, A., Cha, A., Huang, M. Z., Dhami, S., & Pemminati, S. (2025) · Cureus · doi:10.7759/cureus.93123 · Cited by 12
“…of the first GLP-1 receptor agonists to be evaluated in clinical trials for PD. Based on its established safety profile in type 2 diabetes [129] and promising neuroprotective effects in preclinical studies [130], it has become a leading candidate in efforts to repurpose metabolic therapies for PD.”
A new approach to disease-modifying drug trials in Parkinson’s disease
Barker, R. A., Stacy, M. A., & Brundin, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69690 · Cited by 12
Thakur, P., Baraskar, K., Shrivastava, V. K., & Medhi, B. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149176 · Cited by 12
Nakajima, S., Numakawa, T., Adachi, N., Yoon, H. S., Odaka, H., Ooshima, Y., & Kunugi, H. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.052 · Cited by 12
The Role of Insulin and Incretins in Neuroinflammation and Neurodegeneration
(2015) · Immunoendocrinology · doi:10.14800/ie.391 · Cited by 12
“Exendin-4, a degradation-resistant GLP-1 analogue, has been shown to protect primary cortical and dopaminergic neurons exposed to the PD inducing toxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) both in rodent and human cell cultures [77] .”
BackgroundSharma, H. S. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0542-0 · Cited by 12
“Recent studies on identification of genes linked to these neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD) resulted in the development of animal models that could be used for studying mechanism and evaluating new potential therapies ( Li et al. 2009 ).”
BackgroundPhysiology and pharmacology of glucagon-like peptide-1 receptor
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Petrov, V. I., Strygin, A. V., Koryanova, K. N., Gorbunova, Y. V., Kolosov, Y. A., Ivanova, O. V., Pavlova, E. V., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-347-380 · Cited by 13
Gut neuropeptide involvement in Parkinson’s disease
Templeton, H., Tobet, S. A., & Schwerdtfeger, L. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00383.2024 · Cited by 11
Giofrè, F., Zaffina, I., Pelle, M. C., & Arturi, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696419 · Cited by 11
Dhureja, M., & Deshmukh, R. R. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176635 · Cited by 11
Bashir, B., Vishwas, S., Gupta, G., Paudel, K. R., Dureja, H., Kumar, P., Cho, H., Sugandhi, V. V., Kumbhar, P., Disouza, J., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102693 · Cited by 11
DPP4 regulates the inflammatory response in a rat model of febrile seizures
Sun, Q., Zhang, Y., Huang, J., Yu, F., Xu, J., Peng, B., Liu, W., Han, S. H., Yin, J., & He, X. (2017) · Bio-Medical Materials and Engineering · doi:10.3233/bme-171635 · Cited by 11
“Enhancing circulating GLP-1 levels can preserve neurons in an acute stroke model [49].”
Wiberg, S. C., Kjærgaard, J., Schmidt, H., Thomsen, J. H., Frydland, M. S., Winther‐Jensen, M., Lindholm, M. G., Høfsten, D. E., Engstrøm, T., Køber, L., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002814 · Cited by 11
Si, J., Yu, K., Hao, J., Wang, J., & Zhang, L. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251332035 · Cited by 10
“38 These pathways converge on mechanistic target of rapamycin (mTOR) activation, critically regulating autophagic flux and inflammatory responses.”
Sarro, C. D., Tallarico, M., Pisano, M., Gallelli, L., Citraro, R., Sarro, G. D., & Leo, A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175098 · Cited by 10
Tao, J., Yin, S., Song, Y., Zeng, L., Li, S., Liu, N., Sun, H., Fu, Z., Wang, Y., Li, Y., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.062 · Cited by 10
Self-citationA Research Update on Exendin-4 as a Novel Molecule Against Parkinson’s Disease
Singh, N. K., Singh, A., Varshney, M., & Agrawal, R. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230529093314 · Cited by 10
Silva, M. F. P., Alves, P. L., Alponti, R. F., Silveira, P. F., & Abdalla, F. M. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113630 · Cited by 10
Lomis, S. W. N. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000577 · Cited by 10
“Likewise, in the MPTP toxin model of PD, Exendin-4 protected neurons against degeneration, preserved dopamine levels and improved motor function [126].”
BackgroundGlucagon-like Peptide 1, Brain, Neurodegenerative Diseases: A Modern View
Bulgakova, Romanchuk, N., & Treneva, E. V. (2020) · Bulletin of Science and Practice · doi:10.33619/2414-2948/53/19 · Cited by 10
Sinha, P., Chakrabarti, N., Ghosh, N., Mitra, S., Dalui, S., & Bhattacharyya, A. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.12.013 · Cited by 9
The risk of Parkinson’s disease in diabetic people: an updated systematic review and meta-analysis
Azami, M., Moradkhani, A., Afraie, M., Khateri, S., Sharifian, E., Zamani, K., & Moradi, Y. (2023) · Acta Neurologica Belgica · doi:10.1007/s13760-023-02424-6 · Cited by 9
“Accordingly, it is proposed that PPAR-γ, KATP, AMP-activated protein kinase, GLP-1, and DPP-4 are significant targets for neuro-protective and maybe neuro-restorative therapies because of their linkages with PD and diabetes that have been established [13–16].”
De, S., Banerjee, S., Rakshit, P., Banerjee, S., & Kumar, S. K. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291968240429111357 · Cited by 9
An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Wu, P., Liu, Z., Jiang, X., & Fang, H. (2019) · Current Drug Targets · doi:10.2174/1389450120666191031104653 · Cited by 9
Elabi, O. F., Davies, J. S., & Lane, E. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212346 · Cited by 9
Kuo, T., Chen, Y.-H., Wang, V., Huang, E. Y., Ma, K., Greig, N. H., Jung, Y. J., Choi, H.-I., Olson, L., Hoffer, B. J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054687 · Cited by 9
“Likewise, neurotrophic GLP-1R-mediated actions have been demonstrated across both neuronal in vitro and in vivo models, including the development of a stronger cellular phenotype, as evaluated by an increased level of tyrosine hydroxylase immunoreactivity in unchallenged primary dopaminergic cell cultures [28], of cho…”
BackgroundSelf-citationErbaş, O., Saraç, F., Aktuğ, H., & Peker, G. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/946265 · Cited by 9
Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment
Duţă, C., Muscurel, C., Dogaru, C. B., & Stoian, I. A.-M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041516 · Cited by 8
“GLP-1 and Exenatide have been shown to protect human neuroblastoma cells (SH-SY5Y) from H 2 O 2 induced cell death in a dose-dependent manner [101,102].”
Milonas, D., Didangelos, T., Hatzitolios, A. I., & Τζιόμαλος, Κ. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0580-z · Cited by 8
Hatwal, A. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.104049 · Cited by 8
“[10] The benefits of the anti-inflammatory effects of GLP-1 have been extended to neuroinflammtory diseases like ischemic stroke and Parkinson’s.”
Tweaking Energy Metabolism to Prevent and Treat Neurological Disorders
Mattson, M. P., Kapogiannis, D., & Greig, N. H. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.135 · Cited by 8
Self-citationCentral Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection
McGrath, R. T. (2015) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000.152 · Cited by 8
“Administration of exendin-4 was shown to reduce brain damage and improve functional outcome in a transient middle cerebral artery occlusion stroke model, independent of its blood glucose lowering activity [71,72].”
BackgroundGut Hormones Restrict Neurodegeneration in Parkinson’s Disease
Bayliss, J., Stark, R., Reichenbach, A., & B., Z. (2011) · Advanced Understanding of Neurodegenerative Diseases · doi:10.5772/28028 · Cited by 5
INTRAVITREAL CELL-BASED PRODUCTION OF GLUCAGON-LIKE PEPTIDE-1
Zhang, R., Zhang, H., Xu, L., Ma, K., Wallrapp, C., & Jonas, J. B. (2010) · Retina · doi:10.1097/iae.0b013e3181f27509 · Cited by 8
“Glucagon-like peptide-1 is another candidate on this list of potentially neuroprotective agents.(11,12,26) It is a gut hormone and is the most potent endogenous insulinotropic agent with actions that include stimulating adenylate cyclase and protein kinase activity in the b-cell.”
BackgroundWang, H., Ko, H., Leung, T. W. H., Huang, J., Sai, J., Liang, Y., Li, H., Zhang, J., Cao, Q., Zang, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66167-z · Cited by 7
Self-citationChen, K., Hsueh, S., Parekh, P., Batsaikhan, B., Tweedie, D., Luo, W., Patel, C., Chiang, Y. H., Bambakidis, N. C., Hoffer, B. J., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01573-1 · Cited by 7
Self-citationRimal, N., Khanal, S., Bohara, G., & Choi, D. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110643 · Cited by 7
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.30 · Cited by 7
Sculptor and Destroyer: Tales of Glutamate—the Brain's Most Important Neurotransmitter
Mattson, M. P. (2023) · The MIT Press eBooks · doi:10.7551/mitpress/14422.001.0001 · Cited by 7
Self-citationDellaValle, B., Hempel, C., Staalsøe, T., Johansen, F. F., & Kurtzhals, J. A. L. (2016) · Malaria Journal · doi:10.1186/s12936-016-1486-0 · Cited by 7
Exendin-4 Reversed the PC12 Cell Damage Induced by circRNA CDR1as/miR-671/GSK3β Signaling Pathway
Quan, H., Chen, Q., Wang, K., Wang, Q., Lü, M., Zhang, Y., Qiang, S., Xue, S., Lin, H., Zhu, H., et al. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01698-2 · Cited by 7
Levin, J., Nübling, G., Giese, A., Janzen, A., & Oertel, W. H. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01220-y · Cited by 7
GLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know
Abdulrazeq, H., Taman, M., Ali, R., Doberstein, C., Sullivan, P. Z., Sampath, P., Telfeian, A. E., Gokaslan, Z. L., Fridley, J., & Asaad, W. F. (2024) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000098 · Cited by 7
Metadata
- Authors
- Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., Brossi, A., Lahiri, D. K., Mattson, M. P., Hoffer, B. J., Wang, Y., & Greig, N. H.
- Affiliations
- National Institute on Aging (US)
- Medical University of South Carolina (US)
- National Institute on Drug Abuse (US)
- University of North Carolina at Chapel Hill (US)
- Indiana University School of Medicine (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-01-27
- Volume
- 106
- Issue
- 4
- Pages
- 1285-1290
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2633544
- OpenAlex
- W2080785707
- Cited by
- 589
- References
- 45
- Citations by year
- 2026: 18 · 2025: 39 · 2024: 39 · 2023: 24 · 2022: 33 · 2021: 49 · 2020: 41 · 2019: 40 · 2018: 43 · 2017: 34 · 2016: 41 · 2015: 45 · 2014: 34 · 2013: 33 · 2012: 27
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- University of Toronto
- National Institutes of Health
- National Institute on Aging
- National Institute on Drug Abuse
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- GLP-1 receptor, exendin-4, stroke, Parkinson's disease, dopaminergic neurons, cortical neurons, neuroprotection, MPTP mouse model, middle cerebral artery occlusion, 6-hydroxydopamine, hypoxia, oxidative stress, dopamine levels, motor function
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Cells, Cultured, Cerebral Cortex, Disease Models, Animal, Dopamine, Embryo, Mammalian, Gene Expression Regulation, Humans, Mesencephalon, Neurons, Parkinson Disease, Peptides, Venoms, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Cell Hypoxia, Treatment Outcome, Cell Death, Receptors, Glucagon, Cytoprotection, Brain Infarction, Stroke, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.